The objective of the Medicinal Chemistry India project is to continue to build and optimize a basic medicinal chemistry course for industrial and academic scientists in India and other South Asian countries. The initial success of the program, partly supported by IUPAC grant in 2013 [see project 2012-032-2-700] is one of the driving forces to continue our theme of applied chemistry education in relation to drug design and development. Sri Ramachandra University, Chennai, India has generously agreed to host this event and will provide the access to their facility for the period. This 5-day course will enhance the program from the 2013 Course by adding new lectures to cover target validation/identification, high-throughput screening, DMPK and preclinical evaluation of toxicity. The increase in medicinal chemistry employment in Indian and southeast Asian pharmaceutical companies and in Contract Research Organizations (CROs) collaborating with US and European companies has created an ongoing need for chemists to acquire state of the art knowledge of medicinal chemistry.
The increase in Medicinal Chemistry and Drug Discovery employment in Indian and Southeast Asian pharmaceutical companies and in the Contract Research Organizations collaborating with US and European companies has created a need for chemists and drug discovery scientists to acquire state of the art knowledge of medicinal chemistry and other drug discovery areas. This course will emphasize the design strategy that takes into account of drug metabolism and pharmacokinetics (DMPK) and toxicophore. The course will be based on the successful first year program in 2013 and the Drew University Residential School on Medicinal Chemistry, taught annually since 1986 on the Drew University campus in Madison, New Jersey. MCI 2015 will comprise 4.5 days of content, including 18-20 1-hour lectures on topics covering all aspects of medicinal chemistry from target selection and validate to hit identification, hit-to-lead chemistry, and lead optimization. New lectures on preclinical toxicity and clinical development will be added for the 2015 program. Four case history presentations of successful drug discovery programs will also be included. The Course will be taught mainly by faculty from the US, with some from local Indian faculty members also participating. The plan is to increase the number of Indian faculty members in subsequent years. The performance and value of the MCI course will be assessed after the end of the 3-year period, and a decision whether to continue in the same format made at that time. The desired outcome will be to enroll 80-100 attendees each year, and provide them with a strong introduction to the practice of medicinal chemistry in drug discovery. We are actively seeking the participation of other emerging or developing countries such as Singapore, Malaysia, South Africa etc.
Nov 2014 – Project announcement published in Chem. Int. Nov-Dec 2014, p. 21-22; DOI: 10.1515/ci-2014-0618
The 2nd Medicinal Chemistry and Drug Discovery India (2015) residential program was held on 8-12 Feb 2015. This program was co-sponsored by IUPAC, ACS Med.Chem Division and ACS. The program was attended by 105 industrial an academic scientists from India. The program covered topics beyond Medicinal Chemistry with a focus on how other disciplines of drug discovery such as DMPK, Toxicology, Clinical, Biology and Pharmacology, formulation play critical role for a Medicinal Chemist in designing medicines and improving the qualities of Medicine. It was a four and a half-day course with a total of 27 lectures 22 regular lectures; 4 case histories In this program, we have also introduced the concept of Biologics with the emphasis on fundamentals of Biologics Medicines with examples of monoclonal antibody drugs that are becoming the next generation medicines. Also introduced in this session was the targeted drug delivery – Antibody Drug Conjugates-ADC approach. The keynote speakers in the opening day include the American Chemical Society President Dr. Diane G Schmidt. There was participation and encouragement from the ACS President office, ACS publication group and the ACS local India section. We also hosted an Academic-Industry-Govt-Relationship panel to improve the awareness of collaborative Drug Discovery & Development Education was held during evening before reception. The feedback from the participants was very positive. There is lot of enthusiasm for this program to be continued in 2017. Based on the feedback, we will be changing the venue to another location under the same SRU-MCADDI 2017 banner. The Biocon Academy, Bangalore, India has generously agreed to host the 2017 program at their campus. Details of this upcoming course will be updated.
Last updated 16 May 2016